Efficient delivery of VEGF-A mRNA for promoting diabetic wound healing via ionizable lipid nanoparticles

Zha, Wenhui; Wang, Ji; Guo, Zongke; Zhang, Yanhao; Wang, Yan; Dong, Shuo; Liu, Chao; Xing, Hanlei; Li, Xinsong

doi:10.1016/j.ijpharm.2022.122565

Cited by 31 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, a VEGF-A mRNA structure was constructed that included a 5′ cap, VEGF-A, 3′-UTR, and poly(A) tail. The combination of the 5′ cap and poly(A) tail increased mRNA stability, while the 5′ UTR and 3′ UTR regions increased transcription efficacy . Overall, these findings highlight the importance of the 5′ cap structure in regulating mRNA stability and translational properties.…”

Section: Chemical Modifications On Rna Molecules In Preclinical Researchmentioning

confidence: 71%

“…The combination of the 5′ cap and poly(A) tail increased mRNA stability, while the 5′ UTR and 3′ UTR regions increased transcription efficacy. 428 Overall, these findings highlight the importance of the 5′ cap structure in regulating mRNA stability and translational properties. They also demonstrate the potential of modifying the 5′ cap and other components of mRNA to improve its functionality and therapeutic efficacy.…”

Section: Chemical Modifications On Mrnamentioning

confidence: 82%

See 1 more Smart Citation

Chemically Modified Platforms for Better RNA Therapeutics

Shi,

Zhen,

Zhang

et al. 2024

Chem. Rev.

View full text Add to dashboard Cite

RNA-based therapies have catalyzed a revolutionary transformation in the biomedical landscape, offering unprecedented potential in disease prevention and treatment. However, despite their remarkable achievements, these therapies encounter substantial challenges including low stability, susceptibility to degradation by nucleases, and a prominent negative charge, thereby hindering further development. Chemically modified platforms have emerged as a strategic innovation, focusing on precise alterations either on the RNA moieties or their associated delivery vectors. This comprehensive review delves into these platforms, underscoring their significance in augmenting the performance and translational prospects of RNA-based therapeutics. It encompasses an in-depth analysis of various chemically modified delivery platforms that have been instrumental in propelling RNA therapeutics toward clinical utility. Moreover, the review scrutinizes the rationale behind diverse chemical modification techniques aiming at optimizing the therapeutic efficacy of RNA molecules, thereby facilitating robust disease management. Recent empirical studies corroborating the efficacy enhancement of RNA therapeutics through chemical modifications are highlighted. Conclusively, we offer profound insights into the transformative impact of chemical modifications on RNA drugs and delineates prospective trajectories for their future development and clinical integration. CONTENTS1. Introduction 930 2. Current Status and Challenges of RNA Therapeutics in Clinics 933 2.1. Molecular Mechanisms and Clinical Research Progress of RNAs 934 2.1.1. ASO 934 2.1.2. siRNA 934 2.1.3. Aptamer 936 2.1.4. mRNA 936 2.1.5. RNA Therapeutics on the Cusp of Clinical Breakthroughs 938 2.2. Major Challenges of Current RNA Therapeutics in Clinics 940 2.

show abstract

Section: Chemical Modifications On Rna Molecules In Preclinical Researchmentioning

confidence: 71%

Section: Chemical Modifications On Mrnamentioning

confidence: 82%

Chemically Modified Platforms for Better RNA Therapeutics

Shi,

Zhen,

Zhang

et al. 2024

Chem. Rev.

View full text Add to dashboard Cite

show abstract

“…After 14 days of treatment, the average wound area in the treated group was 2.4% compared to 21.4% in the PBS group (Figure 11b,c). [288] Cystic fibrosis is a common autosomal genetic disease that reduces life expectancy and affects approximately one in 2500 births among Caucasians. [289] Patients with cystic fibrosis have a severe deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR), making it an important therapeutic target.…”

Section: Protein Replacement Therapymentioning

confidence: 99%

Engineered mRNA Delivery Systems for Biomedical Applications

Wang,

Zhu,

Gan

et al. 2024

Advanced Materials

Self Cite

View full text Add to dashboard Cite

Messenger RNA (mRNA)‐based therapeutic strategies have shown remarkable promise in preventing and treating a staggering range of diseases. Optimizing the structure and delivery system of engineered mRNA has greatly improved its stability, immunogenicity, and protein expression levels, which has led to a wider range of uses for mRNA therapeutics. In this tutorial review, we first provide a thorough analysis of the optimization strategies used in the structure of mRNA and then describe delivery systems in great detail. Furthermore, we summarize the latest advancements in biomedical engineering for mRNA technology, including its applications in combatting infectious diseases, treating cancer, providing protein replacement therapy, conducting gene editing, and more. Lastly, we offer a perspective on forthcoming challenges and prospects concerning the advancement of mRNA therapeutics. Despite these challenges, mRNA‐based therapeutics remain promising, with the potential to revolutionize disease treatment and contribute to significant advancements in the biomedical field.This article is protected by copyright. All rights reserved

show abstract

“…Currently, various nanocarriers loaded gene therapy agents have been reported. See Table 2 [78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96] for other systems.…”

Section: Genes/proteins/peptidesmentioning

confidence: 99%

Recent Advances in Nano-Drug Delivery Systems for the Treatment of Diabetic Wound Healing

Liu¹,

Wei²,

Zheng³

et al. 2023

IJN

View full text Add to dashboard Cite

Diabetes mellitus (DM) induced wound healing impairment remains a serious health problem and burden on the clinical obligation for high amputation rates. Based on the features of wound microenvironment, biomaterials loading specific drugs can benefit diabetic wound treatment. Drug delivery systems (DDSs) can carry diverse functional substances to the wound site. Nano-drug delivery systems (NDDSs), benefiting from their features related to nano size, overcome limitations of conventional DDSs application and are considered as a developing process in the wound treatment field. Recently, a number of finely designed nanocarriers efficiently loading various substances (bioactive and non-bioactive factors) have emerged to circumvent constraints faced by traditional DDSs. This review describes various recent advances of nano-drug delivery systems involved in mitigating diabetes mellitus-based nonhealing wounds.

show abstract

Efficient delivery of VEGF-A mRNA for promoting diabetic wound healing via ionizable lipid nanoparticles

Cited by 31 publications

References 39 publications

Chemically Modified Platforms for Better RNA Therapeutics

Chemically Modified Platforms for Better RNA Therapeutics

Engineered mRNA Delivery Systems for Biomedical Applications

Recent Advances in Nano-Drug Delivery Systems for the Treatment of Diabetic Wound Healing

Contact Info

Product

Resources

About